Search

Your search keyword '"Anti-HIV Agents therapeutic use"' showing total 32,160 results

Search Constraints

Start Over You searched for: Descriptor "Anti-HIV Agents therapeutic use" Remove constraint Descriptor: "Anti-HIV Agents therapeutic use"
32,160 results on '"Anti-HIV Agents therapeutic use"'

Search Results

1. Prevalence of medication overload among older people with HIV: a MedSafer study.

2. Magnitude of anemia and associated factors among HIV infected children on antiretroviral therapy in Awi zone health facilities, Northwest Ethiopia, 2023.

3. Brief communication: Effect of mobile health intervention on medication time adherence among people living with HIV/AIDS receiving care at selected hospitals in Owerri, Imo State Nigeria.

4. Acceptability of six-monthly PrEP dispensing supported with interim HIV self-testing to simplify PrEP delivery in Kenya: findings from qualitative research.

5. Brief communication: The extent and determinants of viral suppression among patients on protease inhibitor-based Anti-retro-viral therapy undergoing intensive adherence counselling in a public HIV care center in Uganda.

6. Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study.

7. Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084.

8. Brief communication: coagulation profiles of HIV positive patients on antiretroviral therapy (ART) at the Mampong Municipal Hospital, Ashanti-Region, Ghana: a case control study.

9. Level of option B+PMTCT drug adherence with male partner involvement and associated factors among breastfeeding women until 18 months in North Gojjam Zone, Amhara region, Northwest Ethiopia, 2022: a multicentre cross-sectional study.

10. Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals.

11. Patterns of HIV-1 Drug Resistance Observed Through Geospatial Analysis of Routine Diagnostic Testing in KwaZulu-Natal, South Africa.

12. The Role of Peptides in Combatting HIV Infection: Applications and Insights.

13. A gut check: understanding the interplay of the gastrointestinal microbiome and the developing immune system towards the goal of pediatric HIV remission.

14. A Prospective Study of the Medication Regimen Complexity Index and Hospitalization Due to Adverse Drug Reactions Among People Living with HIV.

15. Transmitted drug resistance and molecular transmission network among treatment-naive HIV-1 patients in Wenzhou, China, 2020-2023.

16. Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.

17. Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence.

18. B/F/TAF forgiveness to non-adherence.

19. Development of a pharmacy-based HIV PrEP service delivery intervention for Washington, District of Columbia (DC): A study protocol.

20. Trends in viral load suppression among HIV patients on antiretroviral therapy (ART) at Asante Mampong Municipal Hospital, Ghana: 2019-2023.

21. Alterations in circulating immunoregulatory proteins discriminate poor CD4 T lymphocyte trajectories in people with HIV on suppressive antiretroviral therapy.

22. Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

23. Timing of antiretroviral therapy initiation affects intact HIV reservoirs following analytical treatment interruption.

24. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.

25. Antiretrovirals and Weight Change: Weighing the Evidence.

26. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.

27. Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?

28. VIH : Prophylaxie postexposition dite « de poche ».

29. Lenacapavir: a giant step forward in HIV prevention-but a missed opportunity for achieving equity and access.

30. Prep provision in community organizations: a comparative study with conventional services.

31. Risk and pleasure in the era of pharmacologically safe sex.

32. Reconciling advantages and difficulties: knowledge and perceptions of event-driven PrEP among young people.

33. Perceptions and practices of healthcare providers in providing HIV pre-exposure prophylaxis to trans adolescents and young adults and men who have sex with men.

34. Twice-yearly lenacapavir: A milestone for HIV prevention in young African women.

35. "Someone who hates themself doesn't come for their drugs": Experiences of mental health along the HIV care continuum in South-Central, Uganda.

36. Interventions during Early Infection: Opening a Window for an HIV Cure?

37. Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.

38. Association of ART regimen and adherence to viral suppression: an observational study of a clinical population of people with HIV.

39. Incidence and predictors of common opportunistic infections among children living with HIV at Bahir Dar City, Ethiopia.

40. The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance.

42. Predictors of change in CD4 cell count over time for HIV/AIDS patients on ART follow-up in northern Ethiopia: a retrospective longitudinal study.

43. Time to major adverse drug reactions and its predictors among children on antiretroviral treatment at northwest Amhara selected public hospitals northwest; Ethiopia, 2023.

44. Sweden surpasses the UNAIDS 95-95-95 target: estimating HIV-1 incidence, 2003 to 2022.

45. Letter to the Editor: "Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study": Resource reductions are not equal to cost savings.

46. Rapid antiretroviral therapy and treatment outcomes among people living with HIV: exploring the mediating roles of medication adherence.

47. Response: "Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study": resource reductions are not equal to cost savings.

48. An observational cohort study evaluating PrEP reach, engagement and persistence through a community-based mobile clinic in Miami-Dade County, Florida.

49. Comparison of short-read and long-read next-generation sequencing technologies for determining HIV-1 drug resistance.

50. Experience of the national cohort of pregnant women with HIV and their children in Spain: temporal trends in vertical transmission of HIV and associated infections.

Catalog

Books, media, physical & digital resources